The Orphan Drug Designation is a significant regulatory milestone that can provide a company with financial benefits such as tax credits for clinical trials and fee waivers. Additionally, it can grant market exclusivity for a period after the drug is approved, preventing competitors from selling generic versions. This could lead to increased revenues for Intensity Therapeutics and a potential boost in its stock price.